Parkinson's Disease: Epidemiology Forecast to 2033: Focus on 7MM - US, France, Germany, Italy, Spain, the UK, and Japan
10. Januar 2025 09:13 ET
|
Research and Markets
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Parkinson's Disease: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In 2023, there were 2,636,930...
Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access
03. September 2024 04:58 ET
|
Research and Markets
Dublin, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The "Tardive Dyskinesia (TD) Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been...
Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
05. April 2024 04:36 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Tavapadon Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Global Dyskinesia Pipeline Insight 2024: In-depth Analysis on Emerging Drugs, Companies, and Ongoing Clinical Trials
27. Februar 2024 11:17 ET
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Dyskinesia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The global healthcare industry witnesses a pivotal...
Tardive Dyskinesia Therapeutics Market to Surge to USD 9.56 Billion by 2034, Exhibiting a CAGR of 9.31%
31. Januar 2024 07:42 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tardive Dyskinesia Therapeutics Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
01. August 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Tardive Dyskinesia Therapeutics Market Size to Surpass USD 5.09 billion by 2030, exhibiting a CAGR of 9.1%
23. Mai 2023 06:51 ET
|
Fortune Business Insights
Pune, India, May 23, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022 and is projected to grow...
Autism Spectrum Disorder Treatment Global Market Report 2022: Sector to Grow by 6.47% Annually Through 2033
29. Dezember 2022 07:08 ET
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder Treatment Market by Treatment, Application, Distribution Channel, and by Region - Global Forecast to 2022-2033" report has...
Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight
29. August 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight Dyskinesia Pipeline constitutes 40+ key companies...
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
22. November 2021 10:00 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...